Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs.

Increased multiple antibiotic resistance in the face of declining antibiotic discovery is one of society's most pressing health issues. Antimicrobial peptides represent a promising new class of antibiotics. Here we ask whether it is possible to make small broad spectrum peptides employing minimal assumptions, by capitalizing on accumulating chemical biology information. Using peptide array technology, two large random 9-amino-acid peptide libraries were iteratively created using the amino acid composition of the most active peptides. The resultant data was used together with Artificial Neural Networks, a powerful machine learning technique, to create quantitative in silico models of antibiotic activity. On the basis of random testing, these models proved remarkably effective in predicting the activity of 100,000 virtual peptides. The best peptides, representing the top quartile of predicted activities, were effective against a broad array of multidrug-resistant "Superbugs" with activities that were equal to or better than four highly used conventional antibiotics, more effective than the most advanced clinical candidate antimicrobial peptide, and protective against Staphylococcus aureus infections in animal models.

[1]  C. Fjell,et al.  Identification of novel antibacterial peptides by chemoinformatics and machine learning. , 2009, Journal of medicinal chemistry.

[2]  Håvard Jenssen,et al.  Novel anti-infectives: is host defence the answer? , 2008, Current opinion in biotechnology.

[3]  Artem Cherkasov,et al.  QSAR modeling and computer‐aided design of antimicrobial peptides , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[4]  Artem Cherkasov,et al.  Evaluating Different Descriptors for Model Design of Antimicrobial Peptides with Enhanced Activity Toward P. aeruginosa , 2007, Chemical biology & drug design.

[5]  Kai Hilpert,et al.  Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology , 2007, Nature Protocols.

[6]  Kai Hilpert,et al.  Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion , 2007, Nature Protocols.

[7]  Oreola Donini,et al.  An anti-infective peptide that selectively modulates the innate immune response , 2007, Nature Biotechnology.

[8]  P. Kubes,et al.  The Role of TLR2 In Vivo following Challenge with Staphylococcus aureus and Prototypic Ligands1 , 2006, The Journal of Immunology.

[9]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[10]  Thomas Engel,et al.  Basic Overview of Chemoinformatics , 2006, J. Chem. Inf. Model..

[11]  Gregory Stephanopoulos,et al.  A linguistic model for the rational design of antimicrobial peptides , 2006, Nature.

[12]  Kai Hilpert,et al.  Sequence requirements and an optimization strategy for short antimicrobial peptides. , 2006, Chemistry & biology.

[13]  Vladimir Frecer,et al.  QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1. , 2006, Bioorganic & medicinal chemistry.

[14]  Artem Cherkasov,et al.  Comparative QSAR- and Fragments Distribution Analysis of Drugs, Druglikes, Metabolic Substances, and Antimicrobial Compounds , 2006, J. Chem. Inf. Model..

[15]  H. Sahl,et al.  The co-evolution of host cationic antimicrobial peptides and microbial resistance , 2006, Nature Reviews Microbiology.

[16]  R. Hancock,et al.  Peptide Antimicrobial Agents , 2006, Clinical Microbiology Reviews.

[17]  U. Theuretzbacher,et al.  Nature's clarion call of antibacterial resistance: are we listening? , 2006, Current opinion in investigational drugs.

[18]  Artem Cherkasov,et al.  Can 'Bacterial-Metabolite-Likeness' Model Improve Odds of 'in Silico' Antibiotic Discovery? , 2006, J. Chem. Inf. Model..

[19]  J. Oppenheim,et al.  Alarmins: chemotactic activators of immune responses. , 2005, Current opinion in immunology.

[20]  Kai Hilpert,et al.  High-throughput generation of small antibacterial peptides with improved activity , 2005, Nature Biotechnology.

[21]  R. Geffers,et al.  A Cystic Fibrosis Epidemic Strain of Pseudomonas aeruginosa Displays Enhanced Virulence and Antimicrobial Resistance , 2005, Journal of bacteriology.

[22]  Robert E W Hancock,et al.  Design of host defence peptides for antimicrobial and immunity enhancing activities. , 2005, Combinatorial chemistry & high throughput screening.

[23]  Håvard Jenssen,et al.  Modelling of anti‐HSV activity of lactoferricin analogues using amino acid descriptors , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[24]  Y. Kaznessis,et al.  Protegrin structure–activity relationships: using homology models of synthetic sequences to determine structural characteristics important for activity , 2005, Peptides.

[25]  Artem Cherkasov Inductive QSAR Descriptors. Distinguishing Compounds with Antibacterial Activity by Artificial Neural Networks , 2005 .

[26]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Artem Cherkasov,et al.  Inductive Electronegativity Scale. Iterative Calculation of Inductive Partial Charges , 2003, J. Chem. Inf. Comput. Sci..

[28]  S. Projan,et al.  Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.

[29]  J. Shimada,et al.  In Vivo Antibacterial Activity of S-3578, a New Broad-Spectrum Cephalosporin: Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Experimental Infection Models , 2003, Antimicrobial Agents and Chemotherapy.

[30]  Michael R. Yeaman,et al.  Mechanisms of Antimicrobial Peptide Action and Resistance , 2003, Pharmacological Reviews.

[31]  T. Mak,et al.  Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 , 2002, Nature.

[32]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[33]  Robert E W Hancock,et al.  Role of membranes in the activities of antimicrobial cationic peptides. , 2002, FEMS microbiology letters.

[34]  J. Svendsen,et al.  Antibiotic activity of pentadecapeptides modelled from amino acid descriptors , 2001, Journal of peptide science : an official publication of the European Peptide Society.

[35]  Robert E. W. Hancock,et al.  Improved Derivatives of Bactenecin, a Cyclic Dodecameric Antimicrobial Cationic Peptide , 1999, Antimicrobial Agents and Chemotherapy.

[36]  R. Hancock,et al.  Mode of Action of the Antimicrobial Peptide Indolicidin* , 1996, The Journal of Biological Chemistry.

[37]  J. Hansan The end of an era. , 1996, Journal of aging & social policy.

[38]  R. Hancock,et al.  Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae , 1991, Antimicrobial Agents and Chemotherapy.

[39]  M Bolognesi,et al.  Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils. , 1988, The Journal of biological chemistry.